A Fresh Chance for Skincare Brands

The weight-loss revolution in the U.S., fueled by GLP-1 drugs like Ozempic, Wegovy, and Mounjaro, is driving significant changes beyond healthcare, notably in the personal care sector. With the prevalence of obesity, diabetes, and prediabetes, these medications offer promising solutions for chronic metabolic conditions.

In 2025, an estimated 12% of U.S. adults are projected to use GLP-1 medications, a number likely to rise with the introduction of Eli Lilly’s GLP-1 pill, Orforglipron, which promotes broader adoption due to its convenience and affordability. However, a side effect known as “Ozempic face”—characterized by sagging or hollow facial features due to rapid weight loss—has become prominent, especially among women, increasing demand for aesthetic solutions.

Consumer brands, particularly in facial skin care, have the opportunity to address this need. For instance, VOL.U.LIFT GLP-1 4D Skin Rebound Complex by Image Skincare targets GLP-1 side effects with promises of firming and plumping, while GLPSGLT serum, or DermaReverse, offers skin-brightening benefits.

Legacy personal care companies like P&G, Unilever, L’Oreal, and J&J have the chance to innovate or reposition products to cater to the needs of GLP-1 users, tapping into the growing market demand for effective and accessible post-weight-loss skincare solutions.

Retailers can also capitalize by offering science-backed, GLP-1-specific skincare options, enhancing their shelf assortments to meet increasing consumer expectations linked to both beauty and health outcomes. Brands that act now can achieve greater relevance and customer loyalty as weight-loss medications transform consumer lifestyles and skincare needs.